Paradigm Biopharmaceuticals Ltd's (ASX:PAR) (OTCMKTS:PBIGF) Dr Jeannie Joughin tells Proactive's Andrew Scott they've received first revenue through physician prescription of Zilosul® to patients via the Therapeutic Goods Administration (TGA) pay-for-use Special Access Scheme (SAS). Under the SAS, Zilosul® has been made available to physicians with SAS approval to treat patients experiencing chronic arthralgia from Ross River Virus (RRV) infection, previous SAS participants seeking re-treatment and other subjects that would not qualify for recruitment into the Para_OA_008 or Para_OA_002 clinical trials.
Paradigm Biopharmaceuticals secures first revenues for Zilosul
